# Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients

> **NCT00699816** · PHASE3 · COMPLETED · sponsor: **GC Cell Corporation** · enrollment: 230 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** Immuncell-LC

## Key facts

- **NCT ID:** NCT00699816
- **Lead sponsor:** GC Cell Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 230 (ACTUAL)
- **Last updated:** 2023-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00699816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00699816, "Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00699816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*